{"name":"Sarepta Therapeutics","slug":"sarepta","ticker":"SRPT","exchange":"NASDAQ","domain":"sarepta.com","description":"Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.","hq":"Cambridge, MA","founded":0,"employees":"835","ceo":"Douglas Ingram","sector":"Gene Therapy / Rare Disease","stockPrice":23.03,"stockChange":-0.05,"stockChangePercent":-0.22,"marketCap":"$2.4B","metrics":{"revenue":2198237000,"revenueGrowth":-32.7,"grossMargin":-7.4,"rdSpend":207239000,"netIncome":-713410000,"cash":801282000,"dividendYield":0,"peRatio":7.6,"fiscalYear":"FY2025"},"revenueBreakdown":[{"name":"Vyondys 53","genericName":"GOLODIRSEN","slug":"golodirsen","revenue":400000000,"yoyGrowth":0,"percentOfTotal":36.4},{"name":"Amondys 45","genericName":"CASIMERSEN","slug":"casimersen","revenue":400000000,"yoyGrowth":0,"percentOfTotal":36.4},{"name":"Exondys 51","genericName":"ETEPLIRSEN","slug":"eteplirsen","revenue":300000000,"yoyGrowth":0,"percentOfTotal":27.3}],"timeline":[{"date":"2016-01-01","label":"Exondys 51 first approved","drug":"Exondys 51","drugSlug":"eteplirsen","type":"approval","sentiment":"positive"},{"date":"2019-01-01","label":"Vyondys 53 first approved","drug":"Vyondys 53","drugSlug":"golodirsen","type":"approval","sentiment":"positive"},{"date":"2021-01-01","label":"Amondys 45 first approved","drug":"Amondys 45","drugSlug":"casimersen","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Exondys 51 patent cliff ($1.1B at risk)","drug":"Exondys 51","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"Vyondys 53 patent cliff ($1.5B at risk)","drug":"Vyondys 53","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":1100000000,"percentOfTotal":100,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"Vyondys 53","genericName":"GOLODIRSEN","slug":"golodirsen","indication":"Duchenne muscular dystrophy","status":"marketed","revenue":400000000},{"name":"Amondys 45","genericName":"CASIMERSEN","slug":"casimersen","indication":"Duchenne muscular dystrophy","status":"marketed","revenue":400000000},{"name":"Exondys 51","genericName":"ETEPLIRSEN","slug":"eteplirsen","indication":"Duchenne muscular dystrophy","status":"marketed","revenue":300000000},{"name":"SRP-4045","genericName":"SRP-4045","slug":"srp-4045","indication":"Duchenne muscular dystrophy","status":"phase_3"},{"name":"AVI-6002","genericName":"AVI-6002","slug":"avi-6002","indication":"Other","status":"phase_1"},{"name":"AVI-4658 for Injection","genericName":"AVI-4658 for Injection","slug":"avi-4658-for-injection","indication":"Other","status":"phase_1"},{"name":"AVI-6003","genericName":"AVI-6003","slug":"avi-6003","indication":"Other","status":"phase_1"},{"name":"SRP-4053","genericName":"SRP-4053","slug":"srp-4053","indication":"Duchenne muscular dystrophy (DMD) with mutations amenable to exon 53 skipping","status":"phase_3"},{"name":"SRP-9003","genericName":"SRP-9003","slug":"srp-9003","indication":"Myotonic dystrophy type 1 (DM1)","status":"phase_3"}]}],"pipeline":[{"name":"Vyondys 53","genericName":"GOLODIRSEN","slug":"golodirsen","phase":"marketed","mechanism":"Vyondys 53 works by binding to specific RNA sequences to prevent the production of a faulty dystrophin protein.","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"Amondys 45","genericName":"CASIMERSEN","slug":"casimersen","phase":"marketed","mechanism":"Amondys 45 works by binding to specific RNA sequences to prevent the production of a faulty protein that causes Duchenne muscular dystrophy.","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"Exondys 51","genericName":"ETEPLIRSEN","slug":"eteplirsen","phase":"marketed","mechanism":"Exondys 51 binds to specific RNA sequences to prevent the skipping of exon 51 during dystrophin mRNA splicing.","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"SRP-4045","genericName":"SRP-4045","slug":"srp-4045","phase":"phase_3","mechanism":"SRP-4045 is a micro-dystrophin gene therapy that aims to treat Duchenne muscular dystrophy by providing a functional copy of the dystrophin gene.","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"AVI-6002","genericName":"AVI-6002","slug":"avi-6002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVI-4658 for Injection","genericName":"AVI-4658 for Injection","slug":"avi-4658-for-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVI-6003","genericName":"AVI-6003","slug":"avi-6003","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SRP-4053","genericName":"SRP-4053","slug":"srp-4053","phase":"phase_3","mechanism":"SRP-4053 is an antisense oligonucleotide that modulates dystrophin production by promoting exon 53 skipping in Duchenne muscular dystrophy patients with mutations amenable to this approach.","indications":["Duchenne muscular dystrophy (DMD) with mutations amenable to exon 53 skipping"],"catalyst":""},{"name":"SRP-9003","genericName":"SRP-9003","slug":"srp-9003","phase":"phase_3","mechanism":"SRP-9003 is an antisense oligonucleotide that reduces production of DMPK protein by targeting mutant DMPK mRNA in myotonic dystrophy type 1.","indications":["Myotonic dystrophy type 1 (DM1)"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"FDA Approves Sarepta's Vyondys 53 for DMD","summary":"The FDA approved Vyondys 53 for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 2-5 years.","drugName":"Vyondys 53","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Sarepta Reports Q3 2023 Earnings","summary":"Sarepta Therapeutics reported its Q3 2023 earnings, with revenue of $173.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-09-18","type":"deal","headline":"Sarepta Partners with Pfizer to Develop Gene Therapies","summary":"Sarepta Therapeutics partnered with Pfizer to develop gene therapies for rare diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxObVBUM2FWQ0ZiTTBQZzBVOXRKdnFTNkR4NHlwUWVuWmJhU1IxVGd2eUo0VDFoT2o5bGQxam9CN0pEcV9IamRpWjVLMmlOSnpTeUR0dlE3YUFPVG5VWlgzYU9lNllwaEJmQXI2V0Rienp2ZklMR202U3cwMWdsVmphYWhyQ1hSV1kteGFsaUplT3daMXVoZkdSNndvc0dONGZsa0xIcXVFcDYyLVFNazBuQmxZUTVGTGYyNGRrZHRfU0RmUVFIWTFxbzNzbTA3bTUtRU9PUEJNNnlaR1k?oc=5","date":"2026-03-25","type":"trial","source":"24/7 Wall St.","summary":"Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St.","headline":"Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout? - 24/7 Wall St.","sentiment":"neutral"},{"date":"2026-03-02","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxOMjRkSnU1SkxGeFZDc0dLdnpQM2xlOXRVLVpQbThBWnBlVEUwRUhFQlJ0SGFIUllWU2oyenRaRnhHcTQ5eFJZclJ0Z3FzV3BPWG5uVDN4bkhzWV9uSzZQMHpsVFFYVFdGZEhUQ1FncFJCM19xOERLQ2lfYWpmbDNZaHktRGU?oc=5","date":"2025-12-03","type":"earnings","source":"Yahoo Finance","summary":"Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report? - Yahoo Finance","headline":"Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPTnVadEd6V0VHMDQ1dGcySFVnWXRMMHRyMnFfV2FvS3ZoM3pHbzJXNTJ4dG01b0psQ0lUbll2cDA3cHh4X25Lb3BrSmJFMEE2SG5GSXNMYWF1TzZmbzE5aWwzQ0ZXZzVZejlFTmxHNUQ0NWJzcm9xa1hNVEwxemVHZ2xYV2N2RUIwZjNIYWJ0YkpBNG5kMUN0RjdobEFBcHVUQlhVUWR6cGVkUUx2NTJ5eEdFZnRPYzkwN0h4UzdRQjBUVERvZ2c?oc=5","date":"2025-11-24","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Arrowhead Pharmaceuticals, In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPaC05a2lmaDFIWXl1ZWtRckgtUlJUX3VGdmRWcHdOTkFOSlJCbFJ3Rjdfb185QXhUMGltenRhRXpoRjlEV3A1X1RUODlXYlpvY3k5RjQyMUR0dFF3dWwtQ2hBOWdMS1VVZjdJNGZQT2o2WDlfTVQySG9uV2JHNmRzZGFKUXF1Ym9pbTVaQkQ3Z3NtdzQ?oc=5","date":"2025-11-24","type":"pipeline","source":"Yahoo Finance","summary":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Yahoo Finance","headline":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNNUM0N2d4V0VQU3BreE5TVmdBTWtsWkVhSEFqZ3FiY0RGNnd5Z2VwLUdlRjd2aHo0Q1FybnBuU3RmNlF3RW5VUmNzNE1BamhZRWY3aGtjaTQwSlZNcTB1NWF5QnVLQ2VsTm5fcDNqYUVWNkNuNUdtQVg1cm94Y0JZRl9DR3N2WDU4QVJFMG80YTczaXd2YmlPN3dsdzJ6OE1ERTRMczc2NlBWdXBsdExaLVB3OHRQTDA0eE1OdUl5dU1lQTYxU0pqQ3FXSQ?oc=5","date":"2025-11-04","type":"trial","source":"Reuters","summary":"Sarepta shares tumble on trial failure, weak Elevidys outlook - Reuters","headline":"Sarepta shares tumble on trial failure, weak Elevidys outlook","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOeV9ndG5iMVNqWk5qSVFaaV91Z1F0dVNsbU9tNFVsYnhmRk15X2paeTc5aVh5ZGg5YndhVE8yNGhweGltMnRLb1dDQ2FHNFNmc0hHNUUtdGlyYVFMai01U1A3SXMyYUc1NjhpUGUxLXJHOGxhZGdWdm9fM1B4dHlZYnF4LUpXRXB4V3FtbEJiRVdtZkRHTVNfc2poSVBsamszSTZBM2o4ZWl2UmdPTm0zdkt3?oc=5","date":"2025-11-04","type":"pipeline","source":"Sahm","summary":"Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It - Sahm","headline":"Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxObmVHZ21qcHlLeXV2ckJhYjhmTHZfM0NTWUZfZExxVjJCNDZxMzJhN1kzY3lVR1V1UzhyY0kzcjhGbDkydDRXU1pQeEctNUdkSU5CTkktZV9zaXZBOUVzVXk3dF9ZSUxnd1NoY3EwUGRXNjZZcEJaY3hmMFRMSnY0ZmhLeUVDQkh6WE5kS1BlMkpwZWVBUzlrRTRNcGZzckJsVnp0Z2pyZnpZN09JbXAxdlNmM280QVk?oc=5","date":"2025-10-02","type":"regulatory","source":"TechStock²","summary":"Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead? - TechStock²","headline":"Sarepta Therapeutics (SRPT) Surges After FDA Greenlights Duchenne Gene Therapy – Is a Rebound Ahead? - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPdmV4OUtjYW9lTThMa1lvY2V2RXVuVmczZXJyRjZaR0ZFRU1BdDhYTTFzYmQzaE1XRUpfNFZidnh1WDAzSS1BYVd2SDBVcW9kWnJXa0gySXUwemRSTnUtd2lybGNwMm8tb3J6emN3ei16dWFVMzBLMUlPN0xXN0tBQTRNaU04eGFEU0lvSFd0bkNOT1ZvQkN2eHhFVQ?oc=5","date":"2025-08-14","type":"pipeline","source":"Investor's Business Daily","summary":"Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - Investor's Business Daily","headline":"Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxQeGt5SkYxYVlrdEFkTUUzVUZBUnpDdTFkdEIyMUpNRHNfYm5xVW9wSU96RS1VTzI3YlQ4RURWUHJwU0o1cTFFZVNnNnYtVVl4RVBOWThNenZpTG9relJtcFlsOFhYZHRKeC1TQnE1cHdHMG5ZMUhNckxTWkdzaFZBSEh6WTBab19qVVJfMTI4a0MySnN1NGQtRVN2UV9DdDEyTnhab2Z2R3BMZElJMmZNM05Zb2tNR09CVktmUDdBRzN0a3U5SWJrdlllclZsZDRodlBZOHFB?oc=5","date":"2025-07-28","type":"pipeline","source":"Business Wire","summary":"Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Business Wire","headline":"Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPaWFQSnJfb282MldScWZTYXRZdHZwakJMRS04bTQyOGlucVZUOFJSdVc2c3hNNzJtMWFZSlg3LUVNejNVMEE0blZLLVFFZ0hsSS1IcHlfa3Z4bDRISlcwTTlsR2JTZHYzSlhzMVJLVnB1bVpUVHJPdTRsVExCQ21YUXJSM3dVRWQxS2FaUW1QVWcwY1lxc2JYVE9EMi03aWRQSDJsN2QtbTNlSHdjRTVN?oc=5","date":"2025-07-22","type":"pipeline","source":"Seeking Alpha","summary":"How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals - Seeking Alpha","headline":"How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZENLY0ZTUkNxcHc0T0hyaG02azVobUlxek9kbThqcXZjZDBobkNSMmdLcjR2T3MtVkhIUDd5c0JoNUFoa3Y2M3pETmRfazhUMVZDUUktWldSZ0g1SGVFMTNSbjE1b3hNNGRncEpmZ0wzSEtSQlNRb0dXc3N0YnVCWTZPeGxxdmJSakR2UFdIZGRVc3hoSEl5algtUW0xcDlmUFVnSkxLWlNzUQ?oc=5","date":"2025-07-17","type":"pipeline","source":"MedCity News","summary":"Sarepta Slashes Staff, Maps Path Forward for Gene Therapy and Narrower Pipeline - MedCity News","headline":"Sarepta Slashes Staff, Maps Path Forward for Gene Therapy and Narrower Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOTWo3RGpnLWtENGxaR2xSaHdEVm1zSW9ScW81d0VYUHZhb3QxMTNGdzY4cmY4SS00SzQ4RmZqdk9xR3hjVTd4VG9HN3pQNVZQR0RIWVRMTFN4eDlkQjZpZzFuYng4bDlSXzlGTTcwT1c1YUttMzZFc1BSWU5PUDlldWNqY1dWRlNHbHQzWnpPeXlXYmk4V0NGM3VZVW9kb1dDX3lodWcwZ2xPYnpVNWVkQg?oc=5","date":"2025-06-16","type":"pipeline","source":"Investopedia","summary":"Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug - Investopedia","headline":"Sarepta Therapeutics Stock Plunges as Second Patient Dies Taking Its Drug","sentiment":"neutral"}],"patents":[{"drugName":"Exondys 51","drugSlug":"eteplirsen","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Vyondys 53","drugSlug":"risdiplam","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":1500000000}],"drugCount":9,"phaseCounts":{"marketed":3,"phase_3":3,"phase_1":3},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Biogen","BioMarin"],"therapeuticFocus":["Gene Therapy","Rare Diseases"],"financials":{"source":"sec_edgar","revenue":2198237000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":2198237000,"period":"2025-12-31"},{"value":399356000,"period":"2025-09-30"},{"value":611091000,"period":"2025-06-30"},{"value":744856000,"period":"2025-03-31"},{"value":1901979000,"period":"2024-12-31"},{"value":467172000,"period":"2024-09-30"}],"grossProfit":-29101000,"grossProfitHistory":[],"rdSpend":207239000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-713410000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":801282000,"cashHistory":[],"totalAssets":3349703000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":23.03,"previousClose":23.08,"fiftyTwoWeekHigh":64.8,"fiftyTwoWeekLow":10.42,"fiftyTwoWeekRange":"10.42 - 64.8","fiftyDayAverage":18.83,"twoHundredDayAverage":19.43,"beta":0.28,"enterpriseValue":2523062016,"forwardPE":7.6,"priceToBook":2.12,"priceToSales":1.1,"enterpriseToRevenue":1.15,"enterpriseToEbitda":-4.11,"pegRatio":0,"ebitda":-613251008,"ebitdaMargin":-27.9,"freeCashflow":95917000,"operatingCashflow":-205479008,"totalDebt":1039548032,"debtToEquity":91.1,"currentRatio":2.32,"returnOnAssets":-11.2,"returnOnEquity":-53.5,"analystRating":"2.8 - Hold","recommendationKey":"hold","numberOfAnalysts":23,"targetMeanPrice":21.7,"targetHighPrice":38,"targetLowPrice":5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.2,"institutionHeldPercent":90.1,"sharesOutstanding":104989772,"floatShares":91782059,"sharesShort":22887634,"shortRatio":10.4,"shortPercentOfFloat":21.8,"epsTrailing":-7.13,"epsForward":3.04,"revenuePerShare":21.96,"bookValue":10.87,"officers":[{"age":62,"name":"Mr. Douglas S. Ingram Esq., J.D.","title":"CEO & Director"},{"age":49,"name":"Mr. Ian Michael Estepan","title":"President & COO"},{"age":47,"name":"Dr. Louise R. Rodino-Klapac Ph.D.","title":"President of Research & Development and Technical Operations"},{"age":null,"name":"Ryan H. Wong","title":"Executive VP & CFO"},{"age":null,"name":"Rachael  Potter Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Tamara  Thornton","title":"Director of Finance, Treasury & Investor Relations"},{"age":null,"name":"Ms. Cristin L. Rothfuss J.D.","title":"Executive Vice President, General Counsel & Company Secretary"},{"age":null,"name":"Ms. Alison  Nasisi","title":"Executive VP & Chief People Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.sarepta.com","phone":"617 274 4000"}}